A robust pipeline of novel, precisely targeted CNS therapies for genetically defined patient populations

ESCAPE Bio is building a diverse pipeline of first- and best-in-class small molecule therapeutics in major areas of unmet need within neurodegeneration.
ESB1609 is a novel, oral, brain-penetrant and selective sphingosine-1-phosphate 5 (S1P5) receptor agonist being developed for Niemann-Pick C disease (NPC) and other neurodegenerative diseases caused by CNS sphingolipid dysmetabolism.

ESCAPE is developing novel, oral, brain-penetrant and highly-selective LRRK2 G2019S kinase inhibitors for the potential treatment Parkinson’s disease (PD) patients with the G2019S LRRK2 variant.

ESCAPE is developing small-molecule allosteric structure modulators that alter ApoE4 protein structure to restore normal ApoE function and will have the potential to treat ApoE4 carriers with Alzheimer’s disease.

APOE4, apolipoprotein E 4; GBA, glucocerebrosidase; IND, investigational new drug; LRRK2, leucine-rich repeat kinase 2; Ph2, Phase 2; S1P5, sphingosine 1-phosphate receptor 5.
ESB1609 (S1P5 SELECTIVE AGONIST)

LRRK2 KINASE INHIBITORS

STRUCTURE MODULATOR OF APOE4 FOR ALZHEIMER’S DISEASE